US Patent 11,040,004: Scope, Claims, Expiration, and Ciprofloxacin Otic Patent Landscape

US Patent 11,040,004 protects a narrow method of treating otitis externa with a single approximately 0.2 mL dose of a 6% micronized ciprofloxacin thermoreversible gel containing 15% to 17% poloxamer 407. The patent does not broadly claim ciprofloxacin for ear infections, ciprofloxacin formulations generally, or all otic gels. Its strongest protection is the combination of formulation, dose, volume, administration technique, and acute otitis externa treatment parameters.

The patent is most closely associated with the OTIPRIO ciprofloxacin otic platform, although the FDA-approved OTIPRIO indication is treatment of bilateral otitis media with effusion in pediatric patients undergoing tympanostomy tube placement, not otitis externa.[1]

What does US Patent 11,040,004 claim?

The independent claim is a method-of-treatment claim with multiple cumulative limitations.

Limitation	Requirement in claim 1
Disease	Otitis externa, or a sign or symptom of otitis externa
Route	Administration into the external ear canal
Dosage form	Aqueous thermoreversible gel
Active ingredient	Micronized ciprofloxacin
Ciprofloxacin concentration	About 6.0% by weight
Thermogelling agent	15% to 17% poloxamer 407
Ciprofloxacin dose	About 12 mg
Administered volume	About 0.2 mL

A competing product must satisfy the entire combination to literally infringe claim 1. A ciprofloxacin otic solution lacking poloxamer 407, a product containing 6% ciprofloxacin but delivered in a different volume, and a thermoreversible gel used for a different indication would not literally meet every limitation of claim 1.

The phrase "about" gives the claim numerical tolerance, but it does not eliminate the need for a meaningful relationship between concentration, volume, and dose. At 6% by weight, a 0.2 mL dose produces approximately 12 mg of ciprofloxacin, assuming a formulation density near 1 g/mL.

How do dependent claims narrow the patent scope?

Claims 2 through 17 add formulation, clinical, microbiological, and delivery limitations.

Claims	Added subject matter	Commercial significance
2	No BHT	Excludes formulations using butylated hydroxytoluene
3	Preservative-free	Protects a preservative-free presentation
4	Tromethamine	Adds a buffer or pH-adjusting component
5	pH of approximately 7.0 to 8.0	Narrows formulation chemistry
6	Bacterial otitis externa	Limits treatment to bacterial disease
7	Specified bacterial pathogens	Covers named Gram-negative and Gram-positive organisms
8	Acute otitis externa	Narrows the disease to the acute form
9	Symptoms for less than six weeks	Adds a temporal clinical limitation
10	Syringe-tip contact with ear canal	Protects a delivery procedure
11	Tip advanced 1 mm to 8 mm beyond the cartilaginous/bony junction	Adds a defined insertion depth
12	Tip advanced approximately 5 mm	Provides a narrower species within claim 11
13	Hydrochloric acid	Adds a formulation component
14	0.4% to 0.6% tromethamine	Narrows claim 4 quantitatively
15	Enumerated signs and symptoms	Covers clinical manifestations of external-ear disease
16	Intermediate or resistant ciprofloxacin strains	Extends the claimed method to specified resistance conditions
17	Symptom onset within 48 hours	Adds an early-treatment limitation

Claims 10 through 12 are particularly unusual because they protect the physical administration procedure, not only the composition. A product administered by drops, a cannula, or a different delivery depth could avoid those narrower claims while remaining potentially relevant to claim 1.

What formulation is protected by US 11,040,004?

The protected formulation is an aqueous, thermoreversible gel based on micronized ciprofloxacin and poloxamer 407.

Core formulation profile

The claim set points to the following formulation architecture:

Micronized ciprofloxacin at approximately 6% by weight.
Poloxamer 407 at 15% to 17% by weight.
Approximately 0.2 mL administered per dose.
Approximately 12 mg ciprofloxacin per dose.
Optional tromethamine.
Optional hydrochloric acid.
pH of approximately 7.0 to 8.0.
No BHT under claim 2.
No preservative under claim 3.

Poloxamer 407 is a temperature-responsive polymer. Such formulations are designed to remain sufficiently flowable during administration and become more viscous after exposure to body temperature. That property can improve residence time in the external ear canal compared with a conventional aqueous solution.

The independent claim does not require tromethamine, hydrochloric acid, a particular pH, preservative-free status, or absence of BHT. Those limitations appear only in dependent claims. A formulation containing the core ciprofloxacin, poloxamer 407, dose, and volume limitations could fall within claim 1 even if it does not satisfy claims 2 through 5 or 13 through 14.

Does the patent cover ciprofloxacin otic drops generally?

No. The patent is materially narrower than a general ciprofloxacin otic patent.

It does not claim:

All ciprofloxacin ear drops.
All ciprofloxacin treatment of otitis externa.
All thermoreversible otic gels.
All ciprofloxacin formulations containing poloxamer.
All doses of ciprofloxacin administered to the external ear canal.
All bacterial ear infections.

The combination of 6% micronized ciprofloxacin, 15% to 17% poloxamer 407, approximately 12 mg per approximately 0.2 mL dose, and treatment of otitis externa defines the commercial center of gravity of the independent claim.

A competing formulation using 0.3% or 0.2% ciprofloxacin solution, such as conventional fluoroquinolone otic products, would ordinarily fall outside claim 1 because it would not meet the 6% concentration and thermoreversible-gel limitations.

What method-of-use protection does US 11,040,004 provide?

The patent has broad subject-matter language in claim 1, followed by narrower clinical embodiments.

Otitis externa coverage

Claim 1 covers treatment of otitis externa or a sign or symptom of the condition. Claim 8 narrows the disease to acute otitis externa. Claim 9 adds a symptom duration of less than six weeks, while claim 17 focuses on symptom onset within 48 hours.

Claim 15 lists symptoms and signs including:

Edema.
Erythema.
Otorrhea.
Otalgia.
Temporary conductive hearing loss.
Ear-canal shedding.
Redness.
Loss of cerumen.
External-ear pain.
External acoustic meatus inflammation.
Itching.
Aural fullness.
Tragus or pinna tenderness.
Diffuse ear-canal edema.

These limitations broaden the clinical use of the patent beyond treatment of a microbiologically confirmed infection. Under claim 1 and claim 15, treatment directed to a sign or symptom may be relevant even where a bacterial pathogen has not been identified.

Pathogen coverage

Claim 7 names a long list of organisms, including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Klebsiella species, Proteus species, Enterobacter cloacae, Morganella morganii, Providencia stuartii, Streptococcus species, Haemophilus influenzae, and Moraxella catarrhalis.

Claim 6 requires association with a bacterial infection. Claim 7 further narrows the method to the listed organisms or combinations. Claim 16 addresses intermediate and resistant bacterial strains to ciprofloxacin, although the claim’s practical scope may depend on how "intermediate and resistant" is interpreted under applicable susceptibility standards.

How strong is the patent estate?

The patent is strongest against a direct copy of the claimed commercial configuration. Its vulnerability increases as a competitor departs from the numerical and delivery limitations.

Strengths

Claim 1 combines formulation and clinical-use limitations.
The dose-volume relationship is commercially specific.
The claim targets a specialized thermoreversible delivery system.
Dependent claims cover preservative-free and BHT-free versions.
Administration-depth claims may capture a proprietary syringe procedure.
The claims cover both treatment of disease and treatment of symptoms.

Potential design-around paths

A competitor could evaluate:

A non-thermoreversible formulation.
A different ciprofloxacin concentration.
A different poloxamer 407 concentration outside 15% to 17%.
A dose volume materially different from 0.2 mL.
A different ciprofloxacin dose.
A different polymer or gel-forming system.
A formulation administered without the claimed syringe-tip insertion.
A labeled indication limited to a condition other than otitis externa.
A product using a different active ingredient, such as ofloxacin.

The doctrine of equivalents could still create risk where a change is insubstantial and performs substantially the same function in substantially the same way to achieve substantially the same result. Numerical changes close to the claimed ranges require a fact-specific analysis.

When does US Patent 11,040,004 lose exclusivity?

The patent’s nominal term is governed by the earliest effective nonprovisional filing date in its priority chain, not by its 2021 issue date. The relevant end date must be confirmed against the USPTO front-page patent-term data, including any patent-term adjustment, terminal disclaimer, or other term modification.[2]

The patent should be modeled as having a statutory life extending into the 2030s, subject to the official term calculation. Patent expiration and FDA regulatory exclusivity are separate rights:

Right	Relevance
Patent term	Blocks making, using, selling, offering for sale, or importing the claimed invention
New-drug exclusivity	Restricts certain FDA approvals for a defined period
Orphan-drug exclusivity	Applies only if the product received orphan designation and approval for the protected use
Pediatric exclusivity	Can add six months to qualifying FDA exclusivity and listed patent terms
Orange Book listing	Determines whether an ANDA applicant must address a listed patent

The patent does not receive a fresh patent term merely because the formulation receives a later FDA approval or is used for a new indication.

What is the FDA and Orange Book status of the claimed product?

The formulation profile is associated with OTIPRIO, a 6% ciprofloxacin otic product developed for administration into the middle ear during tympanostomy tube placement. FDA approved OTIPRIO under NDA 208684 in December 2015.[1]

The approved indication is different from the claimed use in US Patent 11,040,004:

Issue	OTIPRIO	US 11,040,004
Active ingredient	Ciprofloxacin	Micronized ciprofloxacin
Strength	6%	Approximately 6%
Dosage form	Otic suspension/gel platform	Aqueous thermoreversible gel
Approved FDA use	Bilateral otitis media with effusion during tympanostomy tube placement	Otitis externa treatment
Dose profile	0.2 mL, equivalent to approximately 12 mg	Approximately 0.2 mL and 12 mg
Route	Ear administration	External ear canal
Regulatory pathway	NDA	Patent method claims

A method patent is Orange Book-listable only if it claims an approved method of using the drug. A patent directed solely to otitis externa may not qualify for Orange Book listing against an NDA whose approved indication is limited to otitis media with effusion. The listing analysis depends on the patent claims, the approved labeling, and FDA’s use-code determination.[3]

The patent therefore may have limited Hatch-Waxman leverage if it is not listed for the approved NDA indication. It can still create infringement exposure for commercial use of the claimed method, but it may not automatically trigger a Paragraph IV certification requirement in an ANDA directed to the approved OTIPRIO indication.

Are there Paragraph IV challenges to US 11,040,004?

A Paragraph IV challenge would be relevant only if the patent is listed in the Orange Book for the reference drug and the ANDA applicant must certify that the patent is invalid, unenforceable, or will not be infringed.[4]

The practical scenarios are:

Scenario	Paragraph IV consequence
Patent not listed for the reference product	No mandatory Paragraph IV certification to this patent
Patent listed for an approved use	ANDA applicant may need a Paragraph IV certification or section viii carve-out
Use carved out of the ANDA label	Launch may avoid the patented method, subject to induced-infringement risk
Patent expires before ANDA approval	Patent no longer blocks launch, although other patents may remain
ANDA applicant files Paragraph IV notice	Patent holder may sue within 45 days and obtain a 30-month stay under applicable conditions

A generic ciprofloxacin product approved only for conventional otic indications would not necessarily practice the patented method. A generic or follow-on product specifically labeled for a 6% thermoreversible ciprofloxacin gel for acute otitis externa would face substantially higher risk.

What generic launch risks exist?

The greatest generic risk is not conventional ciprofloxacin otic drops. It is a direct or near-direct copy of the 6% thermoreversible gel.

Low-risk launch profile

A conventional generic may reduce risk by using:

A much lower ciprofloxacin concentration.
A simple aqueous solution.
A non-thermoreversible suspension.
A different dosing volume.
An indication limited to an FDA-approved use outside otitis externa.
A label that excludes the patented use.

High-risk launch profile

Risk increases where a product has:

Approximately 6% micronized ciprofloxacin.
15% to 17% poloxamer 407.
Approximately 0.2 mL dosing.
Approximately 12 mg ciprofloxacin per dose.
A label for acute otitis externa.
A syringe-based administration instruction.
A preservative-free or BHT-free formulation matching the dependent claims.

A section viii carve-out may avoid a patented method of use if the FDA-approved labeling can omit that use and the remaining label does not encourage infringement. Promotional materials, physician instructions, dosing instructions, and distributor communications can undermine a nominal carve-out.

Does biosimilar risk apply?

No. Ciprofloxacin is a small-molecule antibacterial, not a biologic. The relevant competitors would use an ANDA, a 505(b)(2) application, or, depending on the product and formulation, a full NDA pathway. The Biosimilar User Fee Act and the FDA Purple Book are not the principal regulatory frameworks for this product.[5]

A 505(b)(2) applicant could face patent certification issues if it relies on an approved ciprofloxacin product while pursuing a new formulation, delivery system, or indication. The patent’s formulation and method claims would be more relevant to a 505(b)(2) product than to a conventional low-strength ciprofloxacin otic solution.

What patent litigation or licensing deals affect the patent?

US Patent 11,040,004 should be analyzed with the related ciprofloxacin otic and thermoreversible-gel patent family rather than in isolation. The key commercial platform is OTIPRIO, originally developed by Otonomy.

The principal diligence issues are:

Whether the patent is assigned to the current owner or remains subject to a security interest.
Whether a terminal disclaimer links its term to a related patent.
Whether continuation or divisional patents remain pending or unexpired.
Whether the patent is listed in the Orange Book for NDA 208684.
Whether the product rights have been licensed, returned, or transferred.
Whether any settlement contains a license, field-of-use restriction, or authorized generic provision.
Whether any litigation concerns related Otonomy patents rather than this specific patent.

The patent number alone does not establish a license, settlement, or infringement judgment. A commercial freedom-to-operate review should examine USPTO assignment records, FDA Orange Book listings, court dockets, and the complete continuation family.

How does this patent compare with conventional otic antibiotics?

Product type	Typical formulation	Relevance to US 11,040,004
Conventional ciprofloxacin solution	Low-strength aqueous solution	Usually outside the claimed 6% gel combination
Ciprofloxacin/hydrocortisone product	Antibiotic plus steroid	Different active and formulation profile
Ofloxacin otic solution	Fluoroquinolone solution	Outside ciprofloxacin-specific claims
6% ciprofloxacin thermoreversible gel	Micronized ciprofloxacin with poloxamer 407	Closest risk profile
Ciprofloxacin suspension for surgical use	High-strength otic product	Potential formulation overlap, but indication and gel limitations matter
Non-antibiotic ear-care product	Acidifying, steroid, or antiseptic formulation	Generally outside the claims

The patent is therefore a platform-specific barrier, not a broad fluoroquinolone barrier.

Key Takeaways

US Patent 11,040,004 is a narrow method patent centered on a 6% micronized ciprofloxacin thermoreversible gel.
Claim 1 requires approximately 0.2 mL, approximately 12 mg ciprofloxacin, and 15% to 17% poloxamer 407.
Dependent claims add preservative-free status, no BHT, tromethamine, pH, hydrochloric acid, pathogens, acute disease, symptom duration, and syringe depth.
Conventional low-strength ciprofloxacin otic solutions are generally outside the independent claim.
A direct copy of the OTIPRIO-type formulation labeled for otitis externa presents the highest infringement risk.
The claimed otitis externa use differs from OTIPRIO’s FDA-approved tympanostomy-tube indication.
Orange Book significance depends on whether the patent claims an FDA-approved method of use and whether FDA accepted a corresponding listing.
Paragraph IV exposure is stronger if the patent is listed for the relevant reference-product use and weaker if the patent is not Orange Book-listed.
Biosimilar analysis does not apply because ciprofloxacin is a small molecule.
The patent should be evaluated with its continuation family, assignment history, Orange Book record, and related Otonomy/OTIPRIO patents.

FAQs About US Patent 11,040,004

Does US 11,040,004 cover Otiprio?

The claim profile closely matches the 6% ciprofloxacin, approximately 0.2 mL, approximately 12 mg otic platform associated with OTIPRIO. The patent’s claimed treatment is otitis externa, while OTIPRIO’s FDA-approved indication is bilateral otitis media with effusion during tympanostomy tube placement.

Can a generic use ciprofloxacin for otitis externa without infringing?

Yes, potentially. A generic using a conventional ciprofloxacin solution or a materially different concentration, polymer system, dose, or volume may avoid claim 1. The analysis must examine the full formulation and labeling.

Does the patent cover a ciprofloxacin gel with a different polymer?

Not literally under claim 1 if the formulation lacks 15% to 17% poloxamer 407. Risk could remain under the doctrine of equivalents, depending on the substitute polymer and the prosecution history.

Are claims 10 to 12 important for device companies?

Yes. Those claims may affect prefilled syringes, applicators, and administration kits that direct the tip beyond the cartilaginous/bony junction. A device can avoid those claims while still implicating claim 1 if the associated formulation and use satisfy the independent claim.

Is a Paragraph IV lawsuit required for every generic ciprofloxacin ear product?

No. The requirement depends on Orange Book listing and the reference product’s approved uses. A generic applicant may use a Paragraph IV certification, a section viii statement, or another pathway depending on the listed patent and proposed labeling.

References

U.S. Food and Drug Administration. (2015). OTIPRIO (ciprofloxacin otic suspension) prescribing information. NDA 208684.
United States Patent and Trademark Office. (2021). U.S. Patent No. 11,040,004, methods of treating otitis externa using ciprofloxacin thermoreversible gel compositions. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2024). Approved biological products and biosimilar products: Purple Book. Center for Drug Evaluation and Research.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alk Abello	OTIPRIO	ciprofloxacin	INJECTABLE, SUSPENSION;OTIC	207986-001	Dec 10, 2015		DISCN	Yes	No	11,040,004	⤷ Start Trial				THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3512513	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2018053173	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,040,004

Which drugs does patent 11,040,004 protect, and when does it expire?

Summary for Patent: 11,040,004